Abstract Background Deoxygenated sickle hemoglobin (HbS) polymerization drives the
pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has …

New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate
event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe …

Voxelotor (Oxbryta™) is a haemoglobin S polymerization inhibitor that has been developed
for the treatment of sickle cell disease. In November 2019, voxelotor received its first global …

Background For decades, patients with sickle cell disease have had only a limited number of
therapies available. In 2019, voxelotor (1500 mg), an oral once-daily sickle haemoglobin …

Background Sickle cell disease (SCD) is a devastating, multisystemic disorder that affects
millions of people worldwide. The earliest clinical manifestations of SCD can affect infants as …

Aims Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb‐
oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs) …

Although the root cause of sickle cell disease is the polymerization of hemoglobin S (HbS) to
form fibers that make red cells less flexible, most drugs currently being assessed in clinical …

Background: Hydroxyurea is the only approved drug for treatment of sickle cell disease.
Objective: To synthesize the published literature on the efficacy, effectiveness, and toxicity of …

Highlights•VOC episodes and low hemoglobin levels are major complications of SCD.•L-
Glutamine decreases the episodes of VOC.•Voxelotor increases hemoglobin levels and …

A major driver of the pathophysiology of sickle cell disease (SCD) is polymerization of
deoxygenated haemoglobin S (HbS), which leads to sickling and destruction of red blood …